Player FM 앱으로 오프라인으로 전환하세요!
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Manage episode 390589137 series 3369804
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
67 에피소드
Manage episode 390589137 series 3369804
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
67 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.